Method of obtaining antiplacental blood, its application for prevention and treatment of postnatal obstetric-gynaecological diseases in cows

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

 

The invention relates to the field of veterinary obstetrics, and can be used for the prevention and treatment of obstetric-gynecological diseases in cows.

In the postpartum period, great changes occur in the endometrium of cows. Caruncula immediately after separation of the placenta covered with a fibrinous effusion. The blood vessels in their reduced and trombicula. In the connective tissue of caruncula there is a large number of cells. Fabric caruncula while gradually disintegrate and otherhas in the uterus, are allocated in the composition lohii. Partial tissue raspravlyalsya of caruncula dissolve. By the 10th day postpartum period on the site of the former caruncula usually are traces of it in the form of a vascular bundle, devoid of epithelium. These and other deprived epithelial areas of the endometrium gradually epiteliziruyutsya.

In optimal conditions, feeding, care, maintenance and proper operation of involution of the genital organs of cows ends up on average 3 weeks after birth, and animals may again occur pregnancy [9].

Because of the inadequate feeding and poor animal welfare, particularly in the absence of walks in the stall period, this process continues until 40 days or more, developing subinvolution of the uterus, the frequency of manifestations of which temperature is t 40-60% and more [3,8].

When subinvolution of the uterus is delayed restoration of the structure of the endometrium, blood vessels of the uterus, its ligaments, retard shrinkage of muscle fibers of the uterus and regression caruncula that can be felt through the rectal wall in cows even on the 7-8th day after calving[1, 2, 3, 4, 5, 6].

On the basis of subinvolution of the uterus often develop acute and chronic endometritis, there is a long violation of the sexual cycles and infertility[1, 2, 3, 4, 5, 6, 7, 8].

The main tasks of modern comprehensive treatment of cows with subinvolution of the uterus is the restoration of the tone and contractility of the uterus, stimulation of regeneration of epithelial tissues in the uterus, increasing the overall resistance of the organism and preventing the development of endometritis [3, 5].

The purpose of our invention is the generation and application of antiplatelet blood (AIC), with therapeutic and preventive action aimed to increase protective forces of the body, accelerate the regeneration of caruncula and involution of the uterus in cows.

Lysates products lysis of various organs, tissues, cells, obtained under the action of their own enzymes (autolysates), acids, alkalis and salts (hydrolysates) or bacteriophage (fagholizata).

To obtain placentalia took 50 grams of sliced caruncula and cotyledons (from cows), which plants the morals in the Cup pestle, dissolved them in 20 ml of warm (+20°C) physiological solution of sodium chloride. The obtained suspension was filtered, and placentalia used within 30 minutes.

To obtain antiplatelet blood (AIC) used young healthy horse, which subcutaneously injected placentalia cows, containing parts of cotyledons and caruncula, at a dose of 20 ml, twice with an interval of 14 days. The introduction of a foreign protein promotes the formation in the body of the horse biologically active substances with directed action, accelerating the dissolution and melting of child and maternal parts of the placenta. 14 days after the second injection of placentalia the horse take blood from the jugular vein and add an anticoagulant.

A known method of using autohemotherapy cows with subinvolution of the uterus or three intramuscular injections of increasing doses of 90, 100, 120 ml with an interval of 48 hours, which has only subsectimeorig activity [3, 5].

However antipattern blood (AIC) in comparison with the conventional Autocraft, in addition to General-stimulating also has a specific action aimed at strengthening resorption caruncula and the remaining parts of the placenta, which accelerates postpartum involution of the genital organs. The effectiveness of APC is enhanced by the background of the use of uterotonic drugs.

Ant the placental blood (AIC) is introduced to stimulate postpartum involution of the genital organs fresh cows and prevention generic (retention of placenta), postpartum obstetric-gynecologic diseases (subinvolution of the uterus, postpartum endometritis) subcutaneously in the neck twice with 10 ml immediately after removal of the fetus and after 6 days.

With the medical purpose for the detention of the placenta, subinvolution of the uterus, postpartum endometritis cows antipattern blood (AIC) is injected subcutaneously in the neck twice 10 ml, with an interval of 6 days.

Tested antiplatelet blood (APC), on the background of complex treatment of patients cows with retention of placenta, subinvolution of the uterus, postpartum endometritis (according to 5 sick animals), showed a high therapeutic efficacy.

When applying antiplatelet blood (AIC) with the preventive purpose 20 fresh cows retention of placenta, subinvolution of the uterus and postpartum endometritis they were not observed. The experimental cows were marked shortening of the period of excretion lohii and involution of the uterus.

Use antiplatelet blood (AIC) reduces the duration of postpartum involution of the genital organs, which allows prevent and reduce the time of treatment of cows with retention of placenta, subinvolution of the uterus and postpartum endometritis.

Sources of information

1. Veterinary obstetrics and gynecology. Under the editorship of Professor G. A. Kononova. - L.: "Kolos" (Leningrad. CTD-n is e), 1977, S. 350-361.

2. Veterinary obstetrics, gynecology and bioengineering breeding / A. P. Studentsov, V. Shipilov S., V. I. Nikitin and others; Ed. by C. I. Nikitin and M. G. Mirolyubov. - 7th ed., revised and enlarged extra - M.: Kolos, 2000, S. 315-317.

3. Goncharov, B. N., Karpov Century A. Prevention and treatment of gynecological diseases of cows. - 2nd ed., Rev. and ext. - M: Rosagropromizdat, 1991, - 190 C.

4. Ermachenko N. N. Obstetrics and gynecology farm animals. Ed. 2nd, Rev. and extra - L.: "Kolos" (Leningrad. separa-tion), 1976, S. 181-182.

5. Sankowski I. F. Prevention and treatment of obstetric and gynecological diseases in cows. - Ufa, Bashkir publishing house, 1982, - 232 C.

6. Logvinov D. D. Pregnancy and parturition in cows. - K.: "Harvest", 1975, S. 209-229.

7. Workshop on obstetrics, gynecology and bioengineering of animal reproduction / C. Y. Nikitin, M., Mirolyubov, V. P. Goncharov and others - M.: Colossus, 2004, S. 158-168.

8. Titova Century and other effects on the involution of the uterus in cows quantum method // Titova Century, Nasibov F., Baitlesov E., Katukov Century, Vlasova,/ Dairy and beef cattle, No. 1, 2006, S. 24-25.

9. Shipilov C. C. Physiological Foundation for the prevention of infertility in cows. M., 1977, - 288 S.

1. The method of obtaining antiplatelet blood (AIC), characterized in that uses the horse, which twice with an interval of 14 days subcutaneously injected placentalia at a dose of 20 ml, containing part to the of Toledano and caruncula cows, and 14 days after the second injection, blood is taken from the jugular vein.

2. Method for the treatment and prevention of detention placenta, subinvolution of the uterus and postpartum endometritis in cows, including application antiplatelet blood (AIC), characterized in that as a drug used antipattern blood (AIC), stimulating postpartum involution of the genital organs fresh cows, which is injected subcutaneously in the neck twice 10 ml, with an interval of 6 days.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: method comprises administering an agent containing gentamicin, gamavit, sodium benzoate, potassium sorbate and propylene glycol. The agent is used in intrauterine mode 2 times a day for 7-10 days at a dose of 5-10 ml to cat and 10-20 ml to dog.

EFFECT: method comprises high therapeutic efficacy in endometritis of cats and dogs.

1 ex

FIELD: medicine.

SUBSTANCE: uterine arteries are embolised, and methotrexate is administered intra-arterially, while a gestational sac is evacuated with a vacuum excochleator assisted with a transabdominaal ultrasonography. The uterine arteries are embolised using Embosphere® and HepaSphere™ microspheres. Methotrexate is administered intra-arterially from a primary blood supply of the gestational sac in a dose of 25 mg with embolysate microparticles using HepaSphere™ microparticles.

EFFECT: method provides the complete block of the blood supply of the gestational sac ensured by the distal and reliable embolisation, the target action of methotrexate on trophoblast tissue that in turn enables reducing the length of vacuum aspiration of the gestational sac in two times, avoiding the potential development of life-threatening bleeding accompanying the gestational sac evacuation, reducing the side effects of the treatment, and preserving the patient's reproductive function and life.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at the postpartum correction of the reproductive functions in cows. Citric, succinic and ascorbic acid taken in ratio 1:2:2 are orally administered into non-milking cows for 10 days before calving in a dose of 15-25 mg/kg of body weight once a day.

EFFECT: using the declared invention enables optimising the metabolic processes, promotes a higher rate of fertilisation and better general natural resistance and immune responsiveness, provides the normal labour and postpartum period.

6 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for the uterine neck preparation for child birth or induced abortion. The agent for the uterine neck preparation for child birth or induced abortion containing propolis ethanol extract, male bee brood homogenate, royal jelly, dried laminaria as active substances; and as an emulsion ointment base, it contains low-molecular polyethylene, Cremophor RH40, Lutrol F-127, hydroxyethyl cellulose and purified water, in certain proportions.

EFFECT: agent has a manifested prolonged action contributing to cervical ripening, as well as additional anti-viral, anti-inflammatory, reparative and antioxidant actions.

1 dwg, 6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, obstetrics, gynecology and includes estimation of puerperas' state, depending on which treatment tactics is selected. Severity of state is estimated by two groups of criteria of table No 3, presented in the description, by 1 point: absence of factors of risk of purulent-septic complications (PSC), subfebrile condition with single rise to 38°C, arrested by antibacterial therapy (ABT), absence of easily arrested intestine paresis after Cesarean section, the cervix of uterus is formed, presence of uterus involution in hysteroscopy at the background of treatment with endometrectomy or vacuum-aspiration, USE-data - increase and extension of uterus cavity by 0.5-1.0 cm, absence of deformation in the area of scar or deformation up to 0.5 cm, on uterus walls - linear echo-positive structures up to 0.2-0.3 cm thick, local sections of reduced myometrium echogenicity in the region of scars not larger than 1.5x1.5 cm, absence of infiltration, hematoma in the region of scars, improvement of laboratory indices in dynamics. Criteria of group 2 are estimated in 2 points: presence of PSC risk factors, long-lasting fever with resumption after finishing ABT, intestine paresis with absence of effect from intensive or repeated treatment courses, absence of tendency to formation of uterus cervix, stable uterus subinvolution, by USE data: extension of uterus cavity ≥1 cm, deformation in scar ≥0.5 cm, echopositive structures ≥0.4 cm, reduces echogenicity in scar zone ≥2.5×1.5 cm, hematoma or infiltrate in retrovesical space, in area of scars, absence of positive dynamics or change of laboratory indices to the worse. If state of puerpera is characterised by criteria of the first group to 7 points, it is estimated as uncomplicated form of disease, if - more than 7 points or at least by one criterion from group 2, as complicated form.

EFFECT: method ensures reliable justification of adequate tactics of patient management, strict control of their state in dynamics, reduction of frequency of complicated generalised forms of PSC, terms of staying in hospital.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to tocology and gynecology and can be used to prepare pregnant women with risk of abnormal birth activity development to childbirth. For this the patients are prescribed to use mifepriston (mifegine), once, 200 mg. In 12 hours after mifepriston use prpidyle-gel is inserted into cervical channel.

EFFECT: full readiness of all reproductive system segments to childbirth within a day thus reducing the level of complicating diseases in childbirth and postnatal period of women, reducing number of emergency operative treatments in the end of the first and in the second period of childbirth.

1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, and namely to obstetrics and gynecology, and can be applied for induction of childbirth. For this purpose per orally mifepristone is taken on first day in dose 200 mg three times after every 4 hours. One day after first intake of mifepristone in back fornix of vagina introduced is dinoproston 1 mg.

EFFECT: method insures preparation of neck of uterus to childbirth, independent delivery without complications in childbirth in case of premature pregnancy in early terms and premature pouring out of amniotic fluid.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. The method involves rectal introduction of cooled sapropelic mud.

EFFECT: method is simple and high-effective.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to obstetrics, and concerns prenatal preparations of full-term pregnant women with premature amenorrhea. That is ensured by the administration of mifepristone 200 mg following amenorrhea immediately in a pregnant woman. The preparation is introduced once more in the same dosage 6 hours later.

EFFECT: invention provides development of regular labour without administering oxytocics with reduced duration of an amenorrhea period and the absence of complications in puerperants and newborns.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to obstetrics, and concerns managing primary uterine inertia (UI). The UI if observed requires amniotomy and intravenous jet introduction of 6% hydroxyethylated starch 500 ml regardless of the generative passage state. If 2 hours after intravenous infusion of starch, the UI is not normalised yet, intravenous introduction of oxytocics - enzaprost or oxytocin by a standard technique. If 4 hours later, the delivery is not terminated yet, intravenous jet introduction of 6% hydroxyethylated starch 500 ml is applied once again.

EFFECT: method provides decreased amount and length of the oxytocics introduction, eliminated adverse reaction thereof.

3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine and is intended for treatment of mastitis in sheep. method includes introduction of medication, containing antibiotic and chemical therapeutic substance, at the background of subcutaneous introduction of oxytocin in dose 10 U two times with 12-hour interval and above-udder novocaine blockade in accordance with D.D.Logvinov, by double introduction of 0.25% novocaine solution in dose 0.5 ml per 1 kg of body weight, with 48-hour interval. Used is preparation, which contains antibiotic norfloxacin as antimicrobial preparation, and dioxydin as chemical therapeutic substance, and additionally 1,2-propyleneflycol, polyvinylpyrrolidone low-molecular, disodium salt of tetraacetic acid ethylenediamine (trilon B), hydrochloric acid (0.1 mol/l) to pH 4.5, water for injections with the following component ratio, wt %: dioxydin - 1.0; norfloxacin - 5.0; 1,2-propyleneflycol - 19.8; polyvinylpyrrolidone low-molecular - 0.2; disodium salt of tetraacetic acid ethylenediamine (trilon B) - 0.01; hydrochloric acid (0.1 mol/l) to pH 4.5-5.5; water for injections - to 100.0. Preparation is introduced intramuscularly in dose o.1 ml/kg of body weight two times per day until clinical recovery, for all forms of mastitis.

EFFECT: claimed invention makes it possible to provide expressed therapeutic effect.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at treating subclinical mastitis in cows. The method involves intracisternal administration of an activated physiologic saline. The activated physiologic saline is administered in the concentration of 600 mg/l in a dose of 20 ml after afternoon milking three days running. Additionally Trivyt 10 ml is intramuscularly injected on the first therapeutic day.

EFFECT: using the declared invention enables more effective treatment and reduced period of recovery.

2 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: therapeutic agent is used as N,N-dimethylamino-prolinamide of oleic acid of the formula 1 , which is used as the aqueous solutions of its salts with pharmacologically acceptable acids.

EFFECT: high therapeutic effect in treatment of endometritis of animals.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and concerns a platform for the delivery of a silver ion releasing compound for treating menorrhagia. The platform comprises a physiologically inert flexible flat spiral sized up to be introduced into a female's uterine cavity, as well as comprises a tissue-necrotising amount of a solid, water-soluble silver salt. The silver ions are delivered to an endometrium to cause the endometrial tissue necrosis. The silver ions stayed inside the uterine cavity can be neutralised by sodium chloride solution delivered to the uterus, e.g. by a catheter, and the carrier can be removed from the uterus.

EFFECT: invention provides extending the range of products, as well as presents the improved agent for treating by more accurate silver nitrate delivery into the uterine cavity.

22 cl, 1 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating anaemia in pregnant women. That is ensured by determining the blood serum iron concentration. If the serum iron concentration is less than 13.0 mcmole/l, chronoferrotherapy combined with hyperbaric oxygenation (HBO) is prescribed. The chronoferrotherapy is conducted for 30-50 days with the use of the Sorbifer Durules preparation taken daily in a single dose in the evening from 8 pm to 10 pm., while the hyperbaric oxygenation is conducted within 5 sessions in the mode of 1.3-1.4 ata pure medical oxygen for 40 minutes.

EFFECT: method provides the higher clinical effectiveness by potentiating the therapeutic effect as a result of the combined action of the HBO and the anti-anaemic preparation; the method is easily reproducible and requires no material costs.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and can be used in integrated therapy of horses suffering from postpartum acute and chronic endometritis. A method for indirect endolymphatic therapy of endometritis in horses consists in lymphotropic administration of Lydase 64 IU dissolved in 0.25% Novocaine 1 ml and then a mixture consisting of polyoxidonium 6 mg, 0.25% Novocaine 100ml, oxytocin 30 IU and a daily unit of the antibiotic gentamicin by means of a universal device for intravenous infusion in the middle of the ischiorectal fossa at a depth of 1.5-2 cm twice every 48 hours.

EFFECT: method enables providing more effective treatment of endometritis in the horses, reducing a probability of side effects and recurrences, as well as cutting the length of treatment.

1 tbl

FIELD: veterinary medicine.

SUBSTANCE: agent for optimisation of the reproductive function of cows comprises fumaric, ascorbic, succinic, and citric acid, based on the dose, mg/kg live body weight: fumaric acid - 3.0-5.0; ascorbic acid - 4.5-7.5; succinic acid - 6.0-10.0; citric acid - 1.5-2.5. The agent is environmentally safe, and its effect on the body of animals is characterized by physiological ability. It activates erythropoiesis and optimizes the redox processes, stabilizes glucose values, total lipids and cholesterol within the preferred physiological standards, supports at high level indicators of components of non-enzymatic link of the antioxidant defence system (vitamins A, C, ceruloplasmin) than consistently provides the content of toxic products of lipid peroxidation (malondialdehyde) within the physiological standards and the optimal level of non-specific resistance of animals after calving.

EFFECT: agent provides optimisation of the reproductive function of cows, reducing the time of involution of genital organs of cows after calving, increasing rate of fertilization and reduction of the length of the service period.

7 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to gynaecology, and can be used in treating such diseases as dysfunctional uterine bleeding, menorrhagia, dysmenorrhoea, endometriosis, uterine fibroid, menopausal disorders, osteoporosis and urogenital atrophy. That is ensured by presenting an urogenital system comprising a frame forming an internal cavity enclosing an insert with a therapeutically effective dose of a biologically active compound. The insert is form-stable and damage-resistant when in use. The frame has an open structure providing access to a main portion of an external portion of the insert. The frame comprises one or more retaining element for frame holding in the uterine. What is also presented is a method for making the above intrauterine system.

EFFECT: group of inventions provides an effective controlled release drug delivery for a long period of time, as well as easy and safe administration and proper removal of the preparation.

14 cl, 9 dwg

FIELD: veterinary medicine.

SUBSTANCE: method of comprehensive treatment of cows with postpartum endometritis comprises repeated subcutaneous injection of preparation of general stimulating nonspecific therapy in conjunction with symptomatic and etiotropic preparations, and the preparation of general stimulating nonspecific therapy is used as tissue biostimulant from the spleen, which is administered subcutaneously five times with an interval between injections of 48÷72 hours with increasing doses of 30, 35, 40, 45 and 50 ml.

EFFECT: enhancing the therapeutic efficacy of treatment of cows with postpartum endometritis, reducing insemination index and duration of infertility.

3 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: method for production of anti-luteolytic blood - AlB is that luteolisate is administered subcutaneously to gelding twice with an interval of 14 days at a dose of 20 ml each, containing parts of the corpus luteum of pregnancy of cows, and after 14 days after the second administration the blood is taken from the jugular vein. The method of treatment and prevention of persistent corpus luteum, subinvolution of uterus and postpartum endometritis in cows comprises at the background of general therapy the use of anti-luteolytic blood that is administered subcutaneously in the neck region twice at a dose of 10 ml each with an interval of 6 days.

EFFECT: use of anti-luteolytic blood promotes the resorption of the corpus luteum of pregnancy and shortens the duration of postpartum involution of genitals that enables to prevent and reduce the time of treatment of ill cows with persistent corpus luteum, subinvolution of uterus and postpartum endometritis.

2 cl

FIELD: medicine.

SUBSTANCE: using the human placental perfusate cells in preparing a therapeutic agent for suppressing tumour cells proliferation in an individual having the tumour cells, wherein the placental perfusate cells represent a collection of nuclear cells of the placental perfusate. Using natural killer cells of CD56+, CD16- recovered from the placenta for preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells. Using the combined natural killer cells in preparing the therapeutic agent for suppressing the tumour cells proliferation in the individual having the tumour cells, wherein the above combined natural killer cells comprise the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used to prepare the above placental perfusate. A method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the human placental perfusate cells, wherein the placental perfusate cells represent the collection of the nuclear cells from the placental perfusate. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cell contact to the number of the natural killer cells prepared of placental CD56+, CD16-. The method for suppressing the tumour cells proliferation in vitro, involving the tumour cells contact to the combined natural killer cells, wherein the above combined natural killer cells involve the natural killer cells recovered from the placental perfusate, and the natural killer cells recovered from the umbilical blood, and wherein the umbilical blood is recovered from the placenta, which is used for prepare the above placental perfusate. A composition applicable in suppressing the tumour cells proliferation, containing the recovered natural killer cells of CD56+, CD16-, wherein the above natural killer cells are recovered from the placental perfusate, and wherein the above natural killer cells make at least 50% cells in the composition.

EFFECT: placental perfusate cells and methods for using them enable suppressing the tumour cells proliferation effectively.

40 cl, 13 tbl, 6 ex, 11 dwg

Up!